Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...

An expert panel of the EU drug regulator endorsed eight new medicines for approval this week, including new indications for ...

Australia’s Therapeutic Goods Administration (TGA) on Wednesday announced that Merck’s Keytruda (pembrolizumab) is the first medicine to have additional indications registered on the Australian ...

Merck’s MRK strong oncology sales growth is largely driven by its biggest revenue driver, Keytruda. The blockbuster PD-L1 ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

Key growth factors for KEYTRUDA include its unparalleled commercial scale, broad approval across multiple tumor types, strong uptake in early-stage therapies, and a robust clinical trial program.